A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria
Chronic Kidney Disease with High Proteinuria
18 Years - 95 Years
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Nov 2023 by AstraZeneca
No locations available
|Experimental: Zibotentan/Dapagliflozin dose A or Zibotentan/Dapagliflozin dose B|
Drug dose (dose A or B) are determined based on eGFR values. Participants will receive daily oral dose of zibotentan/dapagliflozin in fixed dose combination.
Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
|Active Comparator: Dapagliflozin alone|
Participants will receive daily oral dose of dapagliflozin.
Participants will receive dapagliflozin as per the arms they are randomized to